Dermoscribe Psoriasis
FDA Label NDC 69683-201

Full FDA labeling including Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Dermoscribe Pty Ltd for the product Dermoscribe Psoriasis (NDC 69683-201). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding active ingredients, purpose, use, warnings, otc - keep out of reach of children, directions, inactive ingredients, other safety information, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Active Ingredients

LIQUOR CARBONIS DETERGENS 5%, Salicylic Acid 3%

Purpose

TREATMENT OF PSORIASIS.

Use

Dermoscribe's Psoriasis Cream is a topical treatment for relief of Psoriasis.

Warnings

FOR EXTERNAL USE ONLY. 

Seek medical advice before using if pregnant or breastfeeding. If irritation
develops, stop using and seek medical advice. May not be as effective after expiry date.

Otc - Keep Out Of Reach Of Children

KEEP OUT OF REACH OF CHILDREN.

Directions

For use only by persons over 12 years old. Apply in a thin layer over the affected area once or twice daily as required.

Use only in accordance with the directions on the label and within the packaging. Refer to enclosed leaflet for detailed directions.

Inactive Ingredients

AQUEOUS CREAM

Other Safety Information

STORE AT ROOM TEMPERATURE

* Please review the disclaimer below.